{"id":177119,"date":"2025-06-15T00:20:09","date_gmt":"2025-06-15T00:20:09","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/177119\/"},"modified":"2025-06-15T00:20:09","modified_gmt":"2025-06-15T00:20:09","slug":"la-biotech-lyonnaise-phaxiam-placee-en-liquidation-judiciaire","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/177119\/","title":{"rendered":"La biotech lyonnaise Phaxiam plac\u00e9e en liquidation judiciaire"},"content":{"rendered":"<p itemprop=\"description\"><strong>La sentence est tomb\u00e9e : Phaxiam Therapeutics, soci\u00e9t\u00e9 lyonnaise cot\u00e9e, est plac\u00e9e en liquidation judiciaire.<\/strong><\/p>\n<p>Le Tribunal des activit\u00e9s \u00e9conomiques de Lyon a prononc\u00e9 le 11 juin la liquidation judiciaire de Phaxiam Therapeutics, soci\u00e9t\u00e9 lyonnaise biopharmaceutique sp\u00e9cialis\u00e9e dans les traitements innovants contre les infections bact\u00e9riennes r\u00e9sistantes.<\/p>\n<p>Dans son communiqu\u00e9, Phaxiam pr\u00e9cise que \u00ab\u00a0dans le cadre de la proc\u00e9dure de redressement judiciaire, deux offres ont \u00e9t\u00e9 d\u00e9pos\u00e9es mais n&rsquo;ont pas pu aboutir \u00e0 la reprise des actifs de Phaxiam.\u00a0\u00bb\u00a0Le tribunal a d\u00e9sign\u00e9 \u00ab\u00a0Ma\u00eetre Pierre Martin, en tant que liquidateur.\u00a0\u00bb<\/p>\n<p>Cons\u00e9quence directe de cette d\u00e9cision : la soci\u00e9t\u00e9 indique qu\u2019elle \u00ab\u00a0sollicitera aupr\u00e8s d\u2019Euronext la radiation de ses actions, comme cela a d\u00e9j\u00e0 \u00e9t\u00e9 annonc\u00e9.\u00a0\u00bb Elle ajoute qu\u2019 \u00ab\u00a0aucun remboursement des actionnaires ne pourra \u00eatre r\u00e9alis\u00e9.\u00a0\u00bb<\/p>\n<p>Cette issue fait suite \u00e0 plusieurs mois de difficult\u00e9s. \u00ab\u00a0Malgr\u00e9 les initiatives d\u00e9ploy\u00e9es par la Soci\u00e9t\u00e9 et son management pour prolonger son horizon de financement et assurer la continuit\u00e9 de ses op\u00e9rations, les conditions de march\u00e9 tr\u00e8s d\u00e9grad\u00e9es, en particulier pour les soci\u00e9t\u00e9s de biotechnologies cot\u00e9es de petite taille, n&rsquo;ont pas permis de concr\u00e9tiser une solution de refinancement viable\u00a0\u00bb, explique Phaxiam.\u00a0<\/p>\n<p>La soci\u00e9t\u00e9 s\u2019\u00e9tait plac\u00e9e \u00ab\u00a0en redressement judiciaire d\u00e8s le d\u00e9but mars 2025.\u00a0\u00bb<\/p>\n<p>Depuis 2017, Phaxiam affirme avoir permis \u00ab\u00a0\u00e0 plus de 140 patients de b\u00e9n\u00e9ficier de traitements \u00e0 base de phages produits selon les standards pharmaceutiques, sous statut compassionnel. \u00bb Elle \u00ab esp\u00e8re vivement que ces patients pourront continuer \u00e0 \u00eatre suivis et b\u00e9n\u00e9ficier d\u2019un accompagnement m\u00e9dical appropri\u00e9 malgr\u00e9 la fin de ses activit\u00e9s.\u00a0\u00bb<\/p>\n<p>Enfin, dans son communiqu\u00e9, la soci\u00e9t\u00e9 adresse un remerciement \u00ab\u00a0\u00e0 l\u2019ensemble de ses parties prenantes \u2013 collaborateurs, partenaires, professionnels de sant\u00e9 et actionnaires \u2013 pour leur engagement et leur soutien tout au long de son activit\u00e9.\u00a0\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"La sentence est tomb\u00e9e : Phaxiam Therapeutics, soci\u00e9t\u00e9 lyonnaise cot\u00e9e, est plac\u00e9e en liquidation judiciaire. Le Tribunal des&hellip;\n","protected":false},"author":2,"featured_media":177120,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1889],"tags":[1111,11,2813,2190,2430,1109,251,1112,2811,1777,674,118,1011,27,1922,1110,1114,2428,2810,12,241,316,25,2812,517,800],"class_list":{"0":"post-177119","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-lyon","8":"tag-actu","9":"tag-actualites","10":"tag-article","11":"tag-asvel","12":"tag-auvergne-rhone-alpes","13":"tag-breves","14":"tag-culture","15":"tag-depeches","16":"tag-economique","17":"tag-eu","18":"tag-europe","19":"tag-faits-divers","20":"tag-fr","21":"tag-france","22":"tag-info","23":"tag-informations","24":"tag-infos","25":"tag-lyon","26":"tag-lyonmag","27":"tag-news","28":"tag-ol","29":"tag-politique","30":"tag-republique-francaise","31":"tag-sociale","32":"tag-sport","33":"tag-transports"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/114684522040010320","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/177119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=177119"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/177119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/177120"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=177119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=177119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=177119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}